OMass Therapeutics Ltd, Oxford, UK

Q:What is the focus of your lab’s research?
A: We are a platform company leveraging advanced mass spectrometry technologies to support early-stage drug discovery for orphan and immunological diseases. Through our OdyssION™ platform, we combine native MS, biochemistry, and structural biology to directly measure protein–ligand interactions, understand target biology, and identify high-quality drug candidates. By studying intact protein complexes under near-physiological conditions, we gain mechanistic insights into binding, function, and drug action, helping to accelerate the discovery of new therapeutics.

Q:Why did you incorporate the TriVersa^® NanoMate^® into your laboratory?
A: The TriVersa^® NanoMate^® is a key component of our high-throughput native MS platform, enabling automated and reproducible screening of large compound libraries. Coupled to our UHMR Orbitrap systems, it allows us to directly detect and quantify intact protein–ligand complexes under near-native conditions. Its robustness, low sample consumption, and scalability make it an essential tool for delivering the throughput and data quality required for modern drug discovery.

Q:Who would you recommend to purchase the TriVersa^® NanoMate^®?
A: Any laboratory applying native mass spectrometry would benefit from the TriVersa_® NanoMate^®. Its automation, robustness, and reproducibility make it an excellent platform for both high-throughput screening and protein characterization workflows.

Q:Do you have any publications or presentations using the TriVersa^® NanoMate^®?

Peer-reviewed Publications

• Sokratous, K. et al. Enhanced Declustering Enables Native Top-Down Analysis of Membrane Protein Complexes using Ion-Mobility Time-Aligned Fragmentatio.
  Journal of the American Society for Mass Spectrometry (2024). https://pubs.acs.org/doi/abs/10.1021/jasms.4c00190
• Gavriilidou, AFM. et al High-Throughput Native Mass Spectrometry Screening in Drug Discovery.Frontiers in Molecular Biosciences (2022), 9:837901. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.837901/full

Presentations, Webinars & Conference Contributions

• Automated High-Throughput Screening Using Native MS. Protein Metrics Webinar. Available at: https://www.proteinmetrics.com/events/ht-native-screening
• A high-throughput native mass spectrometry-based platform for the screening and characterization of small-molecule drugs. ASMS 2025, Baltimore, MD, USA.
• Sisley, E., et al. High-throughput native mass spectrometry screening platform for hit identification of cytokines. Oral presentation, BMSS Annual Meeting 2025, Edinburgh, UK
• Sokratous, K., et al.  Mass spectrometry-based screening and characterization of electrophile molecules for hit identification of Gasdermin D.
  Oral Presentation, BMSS-BSPR Super Meeting 2024, Warwick, UK.
• Sokratous, K., et al. High-throughput Native Mass Spectrometry screening platform for hit identification of inflammatory targets.
  Oral Presentation, BMSS Annual Meeting 2023, Manchester, UK.